Intrinsic value of Ironwood Pharmaceuticals, Inc. - IRWD

Previous Close

$10.95

  Intrinsic Value

$0.00

stock screener

  Rating & Target

str. sell

-100%

Previous close

$10.95

 
Intrinsic value

$0.00

 
Up/down potential

-100%

 
Rating

str. sell

We calculate the intrinsic value of IRWD stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.7

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  38.70
  35.33
  32.30
  29.57
  27.11
  24.90
  22.91
  21.12
  19.51
  18.06
  16.75
  15.58
  14.52
  13.57
  12.71
  11.94
  11.24
  10.62
  10.06
  9.55
  9.10
  8.69
  8.32
  7.99
  7.69
  7.42
  7.18
  6.96
  6.76
  6.59
Revenue, $m
  481
  651
  862
  1,116
  1,419
  1,773
  2,179
  2,639
  3,153
  3,723
  4,346
  5,023
  5,753
  6,533
  7,363
  8,242
  9,169
  10,143
  11,163
  12,230
  13,342
  14,501
  15,707
  16,962
  18,266
  19,621
  21,030
  22,493
  24,014
  25,596
Variable operating expenses, $m
  655
  886
  1,172
  1,518
  1,929
  2,409
  2,960
  3,585
  4,284
  5,058
  5,903
  6,822
  7,813
  8,872
  10,000
  11,194
  12,453
  13,775
  15,161
  16,609
  18,120
  19,694
  21,332
  23,036
  24,807
  26,648
  28,560
  30,548
  32,614
  34,762
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  655
  886
  1,172
  1,518
  1,929
  2,409
  2,960
  3,585
  4,284
  5,058
  5,903
  6,822
  7,813
  8,872
  10,000
  11,194
  12,453
  13,775
  15,161
  16,609
  18,120
  19,694
  21,332
  23,036
  24,807
  26,648
  28,560
  30,548
  32,614
  34,762
Operating income, $m
  -174
  -235
  -310
  -402
  -510
  -636
  -782
  -947
  -1,131
  -1,335
  -1,556
  -1,799
  -2,060
  -2,339
  -2,637
  -2,952
  -3,283
  -3,632
  -3,998
  -4,379
  -4,778
  -5,193
  -5,625
  -6,074
  -6,541
  -7,026
  -7,531
  -8,055
  -8,600
  -9,166
EBITDA, $m
  -161
  -218
  -288
  -373
  -474
  -592
  -728
  -881
  -1,053
  -1,244
  -1,452
  -1,678
  -1,922
  -2,182
  -2,460
  -2,753
  -3,063
  -3,388
  -3,729
  -4,085
  -4,457
  -4,844
  -5,247
  -5,666
  -6,102
  -6,554
  -7,025
  -7,514
  -8,022
  -8,550
Interest expense (income), $m
  24
  38
  20
  30
  41
  56
  72
  92
  114
  140
  168
  200
  234
  272
  312
  355
  401
  450
  501
  555
  612
  671
  732
  797
  863
  933
  1,005
  1,080
  1,158
  1,239
  1,323
Earnings before tax, $m
  -213
  -255
  -340
  -443
  -565
  -709
  -874
  -1,061
  -1,271
  -1,503
  -1,756
  -2,033
  -2,332
  -2,652
  -2,992
  -3,353
  -3,734
  -4,134
  -4,553
  -4,991
  -5,449
  -5,925
  -6,421
  -6,937
  -7,474
  -8,031
  -8,611
  -9,213
  -9,839
  -10,489
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -213
  -255
  -340
  -443
  -565
  -709
  -874
  -1,061
  -1,271
  -1,503
  -1,756
  -2,033
  -2,332
  -2,652
  -2,992
  -3,353
  -3,734
  -4,134
  -4,553
  -4,991
  -5,449
  -5,925
  -6,421
  -6,937
  -7,474
  -8,031
  -8,611
  -9,213
  -9,839
  -10,489

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  318
  431
  570
  738
  939
  1,172
  1,441
  1,745
  2,086
  2,462
  2,875
  3,322
  3,805
  4,321
  4,870
  5,451
  6,064
  6,708
  7,383
  8,088
  8,824
  9,591
  10,389
  11,218
  12,081
  12,977
  13,908
  14,876
  15,883
  16,929
Adjusted assets (=assets-cash), $m
  318
  431
  570
  738
  939
  1,172
  1,441
  1,745
  2,086
  2,462
  2,875
  3,322
  3,805
  4,321
  4,870
  5,451
  6,064
  6,708
  7,383
  8,088
  8,824
  9,591
  10,389
  11,218
  12,081
  12,977
  13,908
  14,876
  15,883
  16,929
Revenue / Adjusted assets
  1.513
  1.510
  1.512
  1.512
  1.511
  1.513
  1.512
  1.512
  1.512
  1.512
  1.512
  1.512
  1.512
  1.512
  1.512
  1.512
  1.512
  1.512
  1.512
  1.512
  1.512
  1.512
  1.512
  1.512
  1.512
  1.512
  1.512
  1.512
  1.512
  1.512
Average production assets, $m
  80
  108
  143
  185
  236
  294
  362
  438
  523
  618
  721
  834
  955
  1,084
  1,222
  1,368
  1,522
  1,684
  1,853
  2,030
  2,215
  2,407
  2,607
  2,816
  3,032
  3,257
  3,491
  3,734
  3,986
  4,249
Working capital, $m
  28
  38
  50
  65
  82
  103
  126
  153
  183
  216
  252
  291
  334
  379
  427
  478
  532
  588
  647
  709
  774
  841
  911
  984
  1,059
  1,138
  1,220
  1,305
  1,393
  1,485
Total debt, $m
  220
  321
  446
  598
  778
  988
  1,230
  1,504
  1,810
  2,149
  2,520
  2,923
  3,357
  3,822
  4,316
  4,839
  5,391
  5,971
  6,578
  7,213
  7,875
  8,565
  9,283
  10,030
  10,806
  11,612
  12,451
  13,322
  14,227
  15,169
Total liabilities, $m
  286
  388
  513
  665
  845
  1,055
  1,297
  1,571
  1,877
  2,216
  2,587
  2,990
  3,424
  3,889
  4,383
  4,906
  5,458
  6,037
  6,645
  7,279
  7,942
  8,632
  9,350
  10,096
  10,873
  11,679
  12,518
  13,389
  14,294
  15,236
Total equity, $m
  32
  43
  57
  74
  94
  117
  144
  175
  209
  246
  287
  332
  380
  432
  487
  545
  606
  671
  738
  809
  882
  959
  1,039
  1,122
  1,208
  1,298
  1,391
  1,488
  1,588
  1,693
Total liabilities and equity, $m
  318
  431
  570
  739
  939
  1,172
  1,441
  1,746
  2,086
  2,462
  2,874
  3,322
  3,804
  4,321
  4,870
  5,451
  6,064
  6,708
  7,383
  8,088
  8,824
  9,591
  10,389
  11,218
  12,081
  12,977
  13,909
  14,877
  15,882
  16,929
Debt-to-equity ratio
  6.900
  7.450
  7.830
  8.090
  8.290
  8.430
  8.540
  8.620
  8.680
  8.730
  8.770
  8.800
  8.820
  8.850
  8.860
  8.880
  8.890
  8.900
  8.910
  8.920
  8.920
  8.930
  8.940
  8.940
  8.940
  8.950
  8.950
  8.960
  8.960
  8.960
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -213
  -255
  -340
  -443
  -565
  -709
  -874
  -1,061
  -1,271
  -1,503
  -1,756
  -2,033
  -2,332
  -2,652
  -2,992
  -3,353
  -3,734
  -4,134
  -4,553
  -4,991
  -5,449
  -5,925
  -6,421
  -6,937
  -7,474
  -8,031
  -8,611
  -9,213
  -9,839
  -10,489
Depreciation, amort., depletion, $m
  13
  17
  22
  29
  36
  44
  54
  65
  78
  91
  105
  121
  138
  157
  177
  198
  221
  244
  269
  294
  321
  349
  378
  408
  439
  472
  506
  541
  578
  616
Funds from operations, $m
  -199
  -238
  -318
  -414
  -530
  -664
  -820
  -996
  -1,193
  -1,412
  -1,652
  -1,912
  -2,193
  -2,495
  -2,815
  -3,155
  -3,513
  -3,890
  -4,284
  -4,697
  -5,128
  -5,576
  -6,043
  -6,529
  -7,034
  -7,559
  -8,105
  -8,672
  -9,261
  -9,873
Change in working capital, $m
  8
  10
  12
  15
  18
  20
  24
  27
  30
  33
  36
  39
  42
  45
  48
  51
  54
  56
  59
  62
  65
  67
  70
  73
  76
  79
  82
  85
  88
  92
Cash from operations, $m
  -207
  -248
  -330
  -429
  -547
  -685
  -843
  -1,022
  -1,223
  -1,445
  -1,688
  -1,952
  -2,236
  -2,540
  -2,863
  -3,206
  -3,567
  -3,946
  -4,343
  -4,759
  -5,192
  -5,644
  -6,113
  -6,602
  -7,110
  -7,638
  -8,186
  -8,756
  -9,349
  -9,965
Maintenance CAPEX, $m
  -8
  -12
  -16
  -21
  -27
  -34
  -43
  -52
  -63
  -76
  -90
  -105
  -121
  -138
  -157
  -177
  -198
  -221
  -244
  -269
  -294
  -321
  -349
  -378
  -408
  -439
  -472
  -506
  -541
  -578
New CAPEX, $m
  -22
  -28
  -35
  -42
  -50
  -59
  -67
  -76
  -85
  -95
  -104
  -112
  -121
  -130
  -138
  -146
  -154
  -162
  -169
  -177
  -185
  -192
  -200
  -208
  -216
  -225
  -234
  -243
  -253
  -263
Cash from investing activities, $m
  -30
  -40
  -51
  -63
  -77
  -93
  -110
  -128
  -148
  -171
  -194
  -217
  -242
  -268
  -295
  -323
  -352
  -383
  -413
  -446
  -479
  -513
  -549
  -586
  -624
  -664
  -706
  -749
  -794
  -841
Free cash flow, $m
  -238
  -288
  -380
  -492
  -624
  -778
  -953
  -1,151
  -1,372
  -1,615
  -1,881
  -2,169
  -2,478
  -2,808
  -3,158
  -3,529
  -3,919
  -4,328
  -4,757
  -5,204
  -5,671
  -6,157
  -6,663
  -7,188
  -7,735
  -8,302
  -8,892
  -9,505
  -10,143
  -10,806
Issuance/(repayment) of debt, $m
  -194
  101
  125
  152
  180
  210
  242
  274
  306
  339
  371
  403
  434
  465
  494
  523
  552
  580
  607
  635
  662
  690
  718
  747
  776
  807
  838
  871
  906
  942
Issuance/(repurchase) of shares, $m
  496
  267
  354
  460
  586
  732
  901
  1,091
  1,305
  1,541
  1,798
  2,078
  2,380
  2,703
  3,047
  3,411
  3,795
  4,198
  4,620
  5,062
  5,522
  6,002
  6,501
  7,020
  7,560
  8,121
  8,704
  9,310
  9,939
  10,594
Cash from financing (excl. dividends), $m  
  302
  368
  479
  612
  766
  942
  1,143
  1,365
  1,611
  1,880
  2,169
  2,481
  2,814
  3,168
  3,541
  3,934
  4,347
  4,778
  5,227
  5,697
  6,184
  6,692
  7,219
  7,767
  8,336
  8,928
  9,542
  10,181
  10,845
  11,536
Total cash flow (excl. dividends), $m
  64
  80
  99
  119
  141
  165
  189
  214
  239
  264
  288
  312
  337
  360
  383
  406
  428
  449
  471
  492
  513
  535
  557
  579
  602
  625
  650
  675
  702
  730
Retained Cash Flow (-), $m
  -496
  -267
  -354
  -460
  -586
  -732
  -901
  -1,091
  -1,305
  -1,541
  -1,798
  -2,078
  -2,380
  -2,703
  -3,047
  -3,411
  -3,795
  -4,198
  -4,620
  -5,062
  -5,522
  -6,002
  -6,501
  -7,020
  -7,560
  -8,121
  -8,704
  -9,310
  -9,939
  -10,594
Prev. year cash balance distribution, $m
  55
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -377
  -186
  -255
  -341
  -444
  -567
  -712
  -877
  -1,066
  -1,276
  -1,510
  -1,766
  -2,044
  -2,343
  -2,664
  -3,005
  -3,367
  -3,749
  -4,150
  -4,570
  -5,009
  -5,467
  -5,945
  -6,441
  -6,958
  -7,496
  -8,054
  -8,634
  -9,237
  -9,864
Discount rate, %
  15.80
  16.59
  17.42
  18.29
  19.20
  20.17
  21.17
  22.23
  23.34
  24.51
  25.74
  27.02
  28.37
  29.79
  31.28
  32.85
  34.49
  36.21
  38.02
  39.93
  41.92
  44.02
  46.22
  48.53
  50.96
  53.50
  56.18
  58.99
  61.94
  65.03
PV of cash for distribution, $m
  -326
  -137
  -158
  -174
  -185
  -188
  -185
  -176
  -161
  -143
  -122
  -100
  -79
  -61
  -45
  -32
  -22
  -14
  -9
  -6
  -3
  -2
  -1
  0
  0
  0
  0
  0
  0
  0
Current shareholders' claim on cash, %
  50.0
  5.3
  0.6
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).

FINANCIAL RATIOS  of  Ironwood Pharmaceuticals, Inc. (IRWD)

Valuation Ratios
P/E Ratio -19.7
Price to Sales 5.9
Price to Book 24.1
Price to Tangible Book
Price to Cash Flow -64.6
Price to Free Cash Flow -12.5
Growth Rates
Sales Growth Rate 82.7%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 2500%
Cap. Spend. - 3 Yr. Gr. Rate 59.7%
Financial Strength
Quick Ratio 51
Current Ratio 0
LT Debt to Equity 547.8%
Total Debt to Equity 556.7%
Interest Coverage -2
Management Effectiveness
Return On Assets -8.7%
Ret/ On Assets - 3 Yr. Avg. -30%
Return On Total Capital -17.9%
Ret/ On T. Cap. - 3 Yr. Avg. -45.3%
Return On Equity -101.2%
Return On Equity - 3 Yr. Avg. -185.3%
Asset Turnover 0.4
Profitability Ratios
Gross Margin 99.3%
Gross Margin - 3 Yr. Avg. 88.8%
EBITDA Margin -17.2%
EBITDA Margin - 3 Yr. Avg. -99%
Operating Margin -19%
Oper. Margin - 3 Yr. Avg. -103.6%
Pre-Tax Margin -29.9%
Pre-Tax Margin - 3 Yr. Avg. -125.1%
Net Profit Margin -29.9%
Net Profit Margin - 3 Yr. Avg. -125.1%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

IRWD stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the IRWD stock intrinsic value calculation we used $347 million for the last fiscal year's total revenue generated by Ironwood Pharmaceuticals, Inc.. The default revenue input number comes from 0001 income statement of Ironwood Pharmaceuticals, Inc.. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our IRWD stock valuation model: a) initial revenue growth rate of 38.7% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 15.8%, whose default value for IRWD is calculated based on our internal credit rating of Ironwood Pharmaceuticals, Inc., is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Ironwood Pharmaceuticals, Inc..
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of IRWD stock the variable cost ratio is equal to 136.3%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for IRWD stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 9.3% for Ironwood Pharmaceuticals, Inc..

Corporate tax rate of 27% is the nominal tax rate for Ironwood Pharmaceuticals, Inc.. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the IRWD stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for IRWD are equal to 16.6%.

Life of production assets of 6.9 years is the average useful life of capital assets used in Ironwood Pharmaceuticals, Inc. operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for IRWD is equal to 5.8%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $-196.371 million for Ironwood Pharmaceuticals, Inc. - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 154.919 million for Ironwood Pharmaceuticals, Inc. is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Ironwood Pharmaceuticals, Inc. at the current share price and the inputted number of shares is $1.7 billion.

RELATED COMPANIES Price Int.Val. Rating
EXAS Exact Sciences 115.66 1.26  str.sell
NKTR Nektar Therape 34.86 44.57  buy
CPIX Cumberland Pha 6.30 2.39  str.sell
AZN Astrazeneca PL 41.36 24.54  sell
PGNX Progenics Phar 5.20 13.32  str.buy

CONTACT US      

About X-FIN       Privacy policy       Terms of use      

Copyright © X-FIN.com 2005-2019. All rigths reserved.